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Topical photodynamic therapy (PDT) has limitations in the treatment of thick skin tumours. The aim of the study was to evaluate
the eﬀect of pre-PDT deep curettage on tumour thickness in thick (≥2mm) basal cell carcinoma (BCC). Additionally, 3-month
treatment outcome and change of tumour thickness from diagnosis to treatment were investigated. At diagnosis, mean tumour
thickness was 2.3mm (range 2.0–4.0). Pre- and post-curettage biopsies were taken from each tumour prior to PDT. Of 32 veriﬁed
BCCs, tumour thickness was reduced by 50% after deep curettage (P ≤ 0.001). Mean tumour thickness was also reduced from
diagnosis to treatment. At 3-month followup, complete tumour response was found in 93% and the cosmetic outcome was rated
excellent or good in 100% of cases. In conclusion, deep curettage signiﬁcantly reduces BCC thickness and may with topical PDT
provide a favourable clinical and cosmetic short-term outcome.
1.Introduction
Basal cell carcinoma (BCC) is the most common cancer in
the white population, and its incidence is still increasing
[1, 2]. This is a slow-growing, locally invasive epidermal skin
tumour that can cause considerable patient morbidity [3, 4].
BCC most often arises on sun exposed, cosmetic sensitive
s k i na r e a ss u c ha st h ef a c e[ 4].
Amongseveraltherapeuticoptionsavailableforthetreat-
ment of this tumour excision surgery is regarded as the most
eﬀective [5]. However, not all patients are qualiﬁed for sur-
gery. Excision surgery may be challenging in certain ana-
tomic areas, cause cosmetic disﬁgurement, or result in com-
plicationslikescarformationandfunctionalimpairment[6].
Topical PDT, with beneﬁcial cosmesis, may in such cases be
an attractive treatment option [7, 8]. This method involves
the activation of a topically applied photosensitizer by light
in the presence of tissue oxygen, starting a photochemical
reaction in the targeted cells [9].
Five-year clearance rates in BCC from 64 to 81% are re-
ported [10–13].
Evidence-based guidelines support the use of topical
PDT in the treatment of BCC, particularly low risk, superﬁ-
cial lesions [14, 15]. A challenge is the limited penetration of
the photosensitizing agents down to about 1.0 to 2.0mm
depth[16–18]andalsolimitationofredlighttopenetratethe
skin [9]. The treatment eﬃcacy in BCC with thickness
≥2.0mm may therefore be reduced.
AmongseveralstrategiestoincreasePDTeﬀect,pre-treat-
mentcurettagehasbeenshowntoimprovetreatmenteﬃcacy
in nodular tumours [19]. The combination of curettage2 Journal of Skin Cancer
ahead of PDT is today commonly used, even though data to
supports its eﬀect is rare [19, 20].
It is recommended to perform a pre-treatment biopsy to
obtain an indication of tumour thickness [21]. However, the
essential question from a clinical point of view is how thick
the BCC appears after curettage.
Consequently, it is of interest to examine to what extent
tumour thickness may be reduced by deep curettage and ex-
amine to which degree this may aﬀect treatment outcome.
The main objective of this study was to evaluate the eﬀect
of deep curettage on tumour thickness in thick BCC. Addi-
tionally,short-termtreatmenteﬃcacyandcosmesisaswellas
changes in tumour thickness from diagnosis to treatment
were investigated.
2.MaterialandMethod
ThestudywasconductedattheDepartmentofDermatology,
St. Olav’s Hospital HF, Trondheim over a two-year period.
Patients with histological veriﬁed BCC ≥2.0mm thick, selec-
ted for PDT were eligible. The study was approved by the Re-
gional Ethics Committee, and informed consent was obtain-
ed from all patients before study entry.
The size was deﬁned as the mean of the length and width
of the lesion. Pre- and post-curettage biopsies were taken
from the central tumour area by one investigator (EC) using
a 2.0–3.0mm disposable punch biopsy (Stiefel Laboratories
Ltd., Sligo, Ireland). The centre was deﬁned as the midpoint
of the line following the greatest tumour length and was
marked using a skin marker. The biopsies were taken appro-
ximately 0.5mm from either side of the midpoint. In lesions
with a central ulceration, the biopsies were taken outside of
the ulcerated area, along the line following the greatest tu-
mour length, approximately 1.0mm apart. Bleeding after
deep curettage was dried with gauze prior to the taking of
post-curettage biopsy.
The biopsy tissue was ﬁxed in 10% formaldehyde, rou-
tinely processed, embedded in paraﬃn, cut perpendicular to
the skin surface at three places in sections of 4µm, and stain-
ed with haematoxylin, eosin, and saﬀron (HES).
Thehistologicalpreparedslideswereexaminedbypatho-
logists at St. Olav’s University Hospital. The tumour thick-
ness was measured from the stratum corneum to the
bottom of the tumour nest. The pre-curettage biopsies were
classiﬁed histologically as of nonaggressive (nodular) or
aggressive (micronodular and morpheform/inﬁltrative) by
one pathologist.
Toensureaslittlevariationaspossibledeepcurettagewas
performed by one investigator (EC). The procedure was
comprised of an intratumoural debulking within clinical
marginsofthelesionfollowedbymultiplepassesofcurettage
in various directions across the tumour base. A small surgi-
calcurettewasusedtoremovesoft,friabletissueandadispo-
sable 4mm ring curette (Stiefel Laboratories LTD, Sligo, Ire-
land) used to remove hyperkeratosis and crusts and to scrape
clinically ﬁrm tumour areas. In addition, a 4mm broad brim
of normal appearing skin surrounding the tumour was
superﬁcially scraped using a ring curette only to remove stra-
tum corneum.
TheareawasthentreatedwithPDTusingmethylamino-
levulinate (MAL) as a precursor of photosensitive porphy-
rins. MAL cream (Metvix, Galderma, France) was applied
onto the treatment site in a 1mm thick layer and occluded
withalight-shieldingdressing.Anyresidualcreamwaswiped
oﬀ after 3 hours and the area exposed to red light (570–
670nm). A noncoherent LED light source (Aktilite, Galder-
ma, France) was used with a ﬂuence rate of 70–100mW/cm2
and light dose of 37J/cm2.
Eﬃcacy was evaluated by dermatologists through inspec-
tion and palpation three months after treatment and classi-
ﬁed as either in complete response (complete disappearance
of tumour) or as noncomplete response.
The cosmetic outcome in the clinical complete response
areaswasratedona4-pointordinalscaleas(1)excellent(ab-
sence of any stigmata of treatment), (2) good (slightly visible
ﬁbrosis,atrophyorchangeinpigmentation),(3)poor(mod-
erate visible ﬁbrosis, atrophy, or change in pigmentation), or
(4) fair (marked visible ﬁbrosis, atrophy or change in pig-
mentation).
All statistics were calculated using SPSS version 15 (SPSS
Inc., Chicago, IL, USA).
Data distributions were examined by Q-Q plots. Two-
tailed, one-sample Student t-test was used to analyse the
diﬀerences in tumour thickness. Simple linear regression was
used to analyse the association between treatment waiting
time (independent value) and tumour thickness reduction
(dependent value). One-way ANOVA was used to analyse
possiblediﬀerencesintumourreductionandcosmeticresult.
P<0.05 was considered statistically signiﬁcant.
3. Results
A total of 36 patients with each one BCC tumour were in-
cluded. Twenty-one patients were men, mean age 72 years
(range39–92),and15werewomen,meanage77years(range
62–85).
Thirty-four of the tumours were located to scalp or face
a n dt w ol o c a t e dt ot h eb a c k .M e a nl e s i o ns i z ew a s1 1 m m
(range 3–38). The mean diagnostic biopsy tumour thickness
was2.3mm(range2.0–4.0).Theaveragetimefromdiagnosis
to treatment was 91 days (range 13–339). In three cases BCC
was not demonstrated in either the pre- or post-curettage
biopsies. One post-curettage biopsy was lost after ﬁxation.
Thirty-two lesions were included in the analyses. Histologi-
cally, 20 tumours were of nonaggressive and 12 were of ag-
gressive (micronodular = 3, morpheaform/inﬁltrative = 9)
growth type. All data were found to be normally distributed.
Mean tumour thickness before curettage was 2.0mm
(range 0.7–4.0) and after curettage was 1.0mm (range 0.0–
3.1). The diﬀerences between measurements was statistically
signiﬁcant (Table 1). The diﬀerence between pre- and post-
curettage thickness measurements for the aggressive and
nonaggressive subtypes of BCC were also statistically signif-
icant, P = 0.001 (Table 1). In three cases the measurements
before and after curettage were identical. In one case tumour
thickness measurement was 0.1mm greater after curettage.
Ad i ﬀerence between the diagnostic and pre-curettage
mean biopsy measurement of 0.3mm (SD 0.7) was found toJournal of Skin Cancer 3
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Figure 1:Scatter diagramshowingchanges ofBCCthicknessmeas-
urements from diagnosis to treatment. Reduction of thickness is
indicated by positive sign.
be statistically signiﬁcant (P = 0.04). For nonaggressive tu-
mours only, the diﬀerence was 0.34mm (SD 0.6) (P = 0.02)
and for the aggressive subtype it was 0.13mm (SD 0.9) (P =
0.60).
A weak but statistical signiﬁcant linear regression was
found between the treatment waiting time and tumour re-
ductionofthesameperiod(P = 0.03,adjustedr square0.13)
(Figure 1). One patient was clearly an outlier, waiting more
than 300 days before treatment. By excluding this patient
from the analyses, the linear regression was no longer statis-
tically signiﬁcant (P = 0.11).
3.1. Three-Month Follow-Up. Five of the initial 36 included
lesions were missed for 3-month PDT follow-up. Two lesions
intwopatientswereexcisedafterareassessmentoftreatment
shortly after the ﬁrst PDT session. This decision was based
on the post-curettage biopsy tumour thickness measure-
ment, combined with factors as lesion size and location. Fur-
ther, two patients discontinued the scheduled PDT sessions
because of the experience of severe pain during light expo-
sure. They were referred to treatment by excision surgery.
One patient with one lesion died from a non-PDT-related
cause.
Data from the ﬁve dropout patients were excluded from
the data analyses using the per-protocol population (n = 31)
forthe 3-month follow-up. When disregarding the three pre-
and post-curettage non-BCC-veriﬁed cases, noncomplete
response was observed in 2 out of 28 (7%) treated tumours.
One was a nodular tumour with a thickness reduction of
0.4mm and the other was an aggressive subtype showing a
0.1mm increase after curettage.
The cosmetic outcome was rated excellent in 11 of 26
(42%) and good in 15 of 26 (58%) of cases, of which two ex-
amples are demonstrated in Figure 2.
No diﬀerence between tumour thickness reduction after
curettage and the cosmetic outcome was found (P = 0.36).
4. Discussion
The main ﬁnding of this study was a mean 50% reduction
of BCC tumour thickness measurement after deep curettage.
The reduction was signiﬁcant for both the aggressive (no-
dular) and nonaggressive (micronodular and morpheaform/
inﬁltrative) histological subtypes.
Theseﬁndingssupportthepracticeofpre-treatmentcur-
ettage as an eﬀective intervention for tumour thickness re-
duction before the use of PDT in thick BCC.
There are a number of BCCs that are currently diﬃcult
to treat by traditional invasive therapies because of size, site,
or multiple lesion presentation, particularly if trying to avoid
complicationssuchasscarformation.Althoughtreatmentby
topical PDT has been shown to be less eﬀective compared
with excision surgery in nodular BCC [22, 23], cosmetic
outcome for PDT is signiﬁcantly better [22].
Despite the use of deep curettage ahead of PDT, we still
achieved a favourable cosmetic result assessed as good or ex-
cellent in all the evaluated cases.
The 3-month complete response rate of 93% is compa-
rable to published short-term treatment results after MAL-
PDT following curettage showing clearance from 91 to 97%
for superﬁcial and from 82 to 91% for nodular BCC
[11, 22, 24, 25]. However, in these studies the measurement
of tumour thickness was either not stated or was clinically
evaluated only.
Most BCCs appear in the face and neck area [3]o fw h i c h
the nodular and aggressive morpheaform/inﬁltrating types
predominate [26]. Aggressive growth types may penetrate
more deeply into the dermis and are often ﬁbrotic [4]. En-
couraging, therefore, was the present ﬁnding of tumour
thickness reduction to be even more pronounced in the ag-
gressive compared to the nonaggressive type after deep cure-
ttage.
Thereare,however,variousfactorsthatmayhaveaﬀected
the thickness measurements reported in this study. The pre-
and post-curettage punch biopsies were, as described, not
taken from identical tumour areas within the tumour. BCC
can have an irregular growth with inﬁltrating extensions
[27]. The disparity between thickness measurements found
in tissue samples taken from diﬀerent areas of individual
BCC tumours has been shown to increase with increased tu-
mour depth [28]. This may explain why tumour thickness in
one case showed a 0.1mm increase and in three other cases
showed no reduction after curettage. Another source of inac-
curacy may be that sections for histology can “curl up” when
placedontheslides,givingrisetoabbreviatedmeasurements.
Variations of measurement may also be inﬂuenced by several
pathologists being involved. Nevertheless, despite possible
inaccuracies in the measurements, the study results clearly
show that deep curettage in a large number of cases greatly
reduces BCC tumour thickness.
BCCs grow slowly and may take years to double in size
[3]. However, this study demonstrated a signiﬁcant mean tu-
mour thickness reduction of 0.3mm when comparing the
initial diagnostic biopsy with the pre-curettage biopsy mea-
surements. Spontaneous regression of BCC is recognized
[29, 30], and biopsy-induced regression is suggested to occur4 Journal of Skin Cancer
Table 1: Mean BCC tumour thickness measurements, before and after curettage.
Before (mm)
(SD)
After (mm)
(SD)
Diﬀerence (mm)
(95% CI) P-value
BCC tumours included n = 32 2.0 (0.8) 1.0 (0.8) 1.0 (0.7,1.3) P<0.001
Nonaggressive type n = 20 1.9 (0.7) 1.0 (0.7) 0.9 (0.5,1.2) P = 0.001
Aggressive type n = 12 2.3 (0.8) 1.1 (1.0) 1.2 (0.6,1.8) P<0.001
Patient 1
Baseline, 7 ×9mm
Patient 2
Baseline, 25 ×20mm
Patient 1
3 months
Patient 2
3 months
Figure 2: Response to deep curettage and MAL-PDT in thick BCC; patient 1 with a tumour on the temple and patient 2 with a tumour on
the lower cheek. Cosmetic outcome was rated as good in both cases.
in 24% of tumours [31]. Local immune responses involving
acti-vated T-cells inﬁltrating regressing BCCs with apoptosis
of tumour cells may partly explain this phenomenon [30].
Also, BCC is highly dependent on the surrounding stroma
for survival. Wound healing processes including nonspeciﬁc
inﬂammatory responses can disrupt the tumour and its
stroma and may thus play an important role in tumour re-
gression [31].
SimilarmechanismsmayexplainwhyBCCsinthreecases
were not detected in either pre- or post-curettage biopsies
and apparently underwent spontaneous clearance. However,
we cannot exclude sampling error.
In the treatment of BCC, curettage is frequently combin-
ed with other modalities such as surgery, electrodessication,
cryosurgery, and topical PDT. It is commonly performed to
delineate tumour margins and/or to reduce tumour thick-
ness. To what extent curettage exerts an independent eﬀect
on treatment outcome is unclear.
A few studies report on the treatment of small (≤15mm)
tumours and/or selected groups of BCC with curettage alone
[32, 33]. This appears to be eﬀective with long-term recur-
rence rates shown from 8 to 14%, which is comparable to
non-Mohs’standardtherapies.Inafairlyrecentretrospective
studyacurerateof96%includingafavourablecosmeticout-
come was demonstrated [34]. However, historic controls
and/or no speciﬁcation of tumour thickness limit the data in
these studies.
The belief that curettage alone is not suﬃcient to erase all
parts of tumour is, on the other hand, supported by a ﬁnd-
ing in the study by Jih et al. [35] evaluating the ability of cur-
ettage to selectively remove nonmelanoma skin cancer in-
cluding BCC. Overall, the curette left no residual tumour at
the surgical margins in only 12% of cases.
PDT as a topical monotherapy still appears to be a less
attractive option for the treatment of thicker BCC. The com-
bination of PDT and pre-treatment curettage has proved
more eﬀective compared to treatment by placebo cream and
pre-treatment curettage alone. In a randomized, double
blinded study of nodular BCC the complete response rates
were 73% versus 27%, respectively [36].
In a study by Fantini et al. [37], a low response rate of
33%wasreportedfornodularBCCaftertreatmentwithPDT
after removal of only scales and crusts from the surface.
Further,priordebulkingcurettagetoPDTachievedacom-
pleteresponseratefornodularBCCof92%comparedtonon
complete response in the control groups [20]. The controlsJournal of Skin Cancer 5
comprised small numbers of tumours treated with PDT only
and with curettage alone.
These results imply that pre-treatment curettage contri-
bute to make nodular BCC more responsive to topical PDT.
Within the PDT regime, pre-treatment curettage is a
practical, technique-dependant supportive method practised
with great variability. In trying to obtain uniformity of this
procedure, the same investigator performed the curettage in
all cases in the present study. However, it was diﬃcult to
achieve a standardization of the practical exercise, which
again may have inﬂuenced the study results.
The main purpose of deep curettage was to erase the
mainbulkofthetumourwithinitsclinicalmargins.Thepur-
pose was not to remove all parts of the tumour in an attempt
topreventdamageaﬄictedtosurroundingtissue,asreﬂected
by the favourable post-treatment cosmetic results obtained.
5. Conclusion
The study showed a signiﬁcant reduction of tumour thick-
ness in thick BCC after deep curettage. A favourable short-
term eﬃcacy was found, and cosmesis was maintained fol-
lowing deep curettage and PDT.
Topical PDT combined with deep curettage may be con-
sidered as a treatment option of selected thick BCCs in cases
where surgery or other invasive treatment methods are re-
garded as suboptimal.
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